Correspondence 0001193125-24-072581 from Spero Therapeutics, Inc. (SPRO) (CIK 0001701108) (SPRO)
Spero Therapeutics, Inc. (SPRO) (CIK 0001701108)
Date: March 20, 2024 · CIK: 0001701108 · Accession: 0001193125-24-072581
AI Filing Summary & Sentiment
File numbers found in text: 333-277998
Letter
Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
March 20, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Attention: Cindy Polynice
RE: Spero Therapeutics, Inc.
Registration Statement on Form S-3 File No. 333-277998
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Spero Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-277998) (the “Registration Statement”), so that it may become effective at 4:00 p.m., Washington, D.C. time on March 22, 2024 or as soon as possible thereafter.
The Company hereby authorizes Matthew J. Gardella, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Gardella at (617) 348-1735 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Mr. Gardella.
Very truly yours,
SPERO THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 March 20, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice RE: Spero Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-277998 Request for Acceleration of Effectiveness Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Spero Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-277998) (the “Registration Statement”), so that it may become effective at 4:00 p.m., Washington, D.C. time on March 22, 2024 or as soon as possible thereafter. The Company hereby authorizes Matthew J. Gardella, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration. The Company respectfully requests that it be notified of such effectiveness by a telephone call to Mr. Gardella at (617) 348-1735 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Mr. Gardella. Very truly yours, SPERO THERAPEUTICS, INC. /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer, Chief Business Officer and Treasurer cc: Spero Therapeutics, Inc. Satyavrat Shukla, President and Chief Executive Officer Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Matthew J. Gardella, Esq. Matthew Tikonoff, Esq. Lewis J. Geffen, Esq.